Cargando…

Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose‐lowering effects

AIMS/INTRODUCTION: Insulin degludec/insulin aspart (IDegAsp) is a soluble co‐formulation of long‐acting insulin degludec (IDeg) and rapid‐acting insulin aspart (IAsp). The present study investigated the pharmacodynamic properties of IDegAsp in Japanese patients with type 1 diabetes mellitus. MATERIA...

Descripción completa

Detalles Bibliográficos
Autores principales: Haahr, Hanne, Sasaki, Tomio, Bardtrum, Lars, Ikushima, Ippei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931208/
https://www.ncbi.nlm.nih.gov/pubmed/27181070
http://dx.doi.org/10.1111/jdi.12461
_version_ 1782440847964372992
author Haahr, Hanne
Sasaki, Tomio
Bardtrum, Lars
Ikushima, Ippei
author_facet Haahr, Hanne
Sasaki, Tomio
Bardtrum, Lars
Ikushima, Ippei
author_sort Haahr, Hanne
collection PubMed
description AIMS/INTRODUCTION: Insulin degludec/insulin aspart (IDegAsp) is a soluble co‐formulation of long‐acting insulin degludec (IDeg) and rapid‐acting insulin aspart (IAsp). The present study investigated the pharmacodynamic properties of IDegAsp in Japanese patients with type 1 diabetes mellitus. MATERIALS AND METHODS: In this randomized, double‐blind, two‐period, cross‐over trial, 21 Japanese patients with type 1 diabetes mellitus received single doses of 0.5 U/kg IDegAsp and biphasic insulin aspart 30 in a randomized sequence (13–21 days washout between treatments). The pharmacodynamic response was evaluated in a 26‐h euglycemic glucose clamp (target 5.5 mmol/L). Single‐dose IDegAsp glucose infusion rate (GIR) profiles were extrapolated to steady state using modeling. RESULTS: The IDegAsp single‐dose GIR profile showed a clear distinction between the effects of the bolus (IAsp) and basal (IDeg) components in IDegAsp. When simulated to steady state, the GIR profile of IDegAsp was shifted upwards compared with the single‐dose profile, and showed a rapid onset of action and a distinct peak from the IAsp component followed by a separate and sustained basal action from the long‐acting IDeg component. For biphasic insulin aspart 30, the initial shape of the GIR profile was similar to IDegAsp, but GIR continuously decreased from maximum and reached zero 18–20 h post‐dosing. The characteristics of the GIR profile for IDegAsp were retained when simulated to steady state in a twice‐daily dosing regimen. DISCUSSION: In Japanese patients with type 1 diabetes mellitus, the pharmacodynamic profile of IDegAsp is characterized by distinct prandial and basal effects from the IAsp and IDeg components, consistent with what has been reported previously in Caucasian patients with type 1 diabetes mellitus.
format Online
Article
Text
id pubmed-4931208
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-49312082016-07-06 Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose‐lowering effects Haahr, Hanne Sasaki, Tomio Bardtrum, Lars Ikushima, Ippei J Diabetes Investig Articles AIMS/INTRODUCTION: Insulin degludec/insulin aspart (IDegAsp) is a soluble co‐formulation of long‐acting insulin degludec (IDeg) and rapid‐acting insulin aspart (IAsp). The present study investigated the pharmacodynamic properties of IDegAsp in Japanese patients with type 1 diabetes mellitus. MATERIALS AND METHODS: In this randomized, double‐blind, two‐period, cross‐over trial, 21 Japanese patients with type 1 diabetes mellitus received single doses of 0.5 U/kg IDegAsp and biphasic insulin aspart 30 in a randomized sequence (13–21 days washout between treatments). The pharmacodynamic response was evaluated in a 26‐h euglycemic glucose clamp (target 5.5 mmol/L). Single‐dose IDegAsp glucose infusion rate (GIR) profiles were extrapolated to steady state using modeling. RESULTS: The IDegAsp single‐dose GIR profile showed a clear distinction between the effects of the bolus (IAsp) and basal (IDeg) components in IDegAsp. When simulated to steady state, the GIR profile of IDegAsp was shifted upwards compared with the single‐dose profile, and showed a rapid onset of action and a distinct peak from the IAsp component followed by a separate and sustained basal action from the long‐acting IDeg component. For biphasic insulin aspart 30, the initial shape of the GIR profile was similar to IDegAsp, but GIR continuously decreased from maximum and reached zero 18–20 h post‐dosing. The characteristics of the GIR profile for IDegAsp were retained when simulated to steady state in a twice‐daily dosing regimen. DISCUSSION: In Japanese patients with type 1 diabetes mellitus, the pharmacodynamic profile of IDegAsp is characterized by distinct prandial and basal effects from the IAsp and IDeg components, consistent with what has been reported previously in Caucasian patients with type 1 diabetes mellitus. John Wiley and Sons Inc. 2016-02-04 2016-07 /pmc/articles/PMC4931208/ /pubmed/27181070 http://dx.doi.org/10.1111/jdi.12461 Text en © 2015 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Articles
Haahr, Hanne
Sasaki, Tomio
Bardtrum, Lars
Ikushima, Ippei
Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose‐lowering effects
title Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose‐lowering effects
title_full Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose‐lowering effects
title_fullStr Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose‐lowering effects
title_full_unstemmed Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose‐lowering effects
title_short Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose‐lowering effects
title_sort insulin degludec/insulin aspart in japanese patients with type 1 diabetes mellitus: distinct prandial and basal glucose‐lowering effects
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931208/
https://www.ncbi.nlm.nih.gov/pubmed/27181070
http://dx.doi.org/10.1111/jdi.12461
work_keys_str_mv AT haahrhanne insulindegludecinsulinaspartinjapanesepatientswithtype1diabetesmellitusdistinctprandialandbasalglucoseloweringeffects
AT sasakitomio insulindegludecinsulinaspartinjapanesepatientswithtype1diabetesmellitusdistinctprandialandbasalglucoseloweringeffects
AT bardtrumlars insulindegludecinsulinaspartinjapanesepatientswithtype1diabetesmellitusdistinctprandialandbasalglucoseloweringeffects
AT ikushimaippei insulindegludecinsulinaspartinjapanesepatientswithtype1diabetesmellitusdistinctprandialandbasalglucoseloweringeffects